Patents by Inventor Masuo Yamaoka

Masuo Yamaoka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140256693
    Abstract: The present invention mainly aims to provide a drug for the prophylaxis or treatment of androgen-independent prostate cancer, which is highly useful as a pharmaceutical agent. The present invention provides a drug for the prophylaxis or treatment of androgen-independent prostate cancer, containing a steroid C17,20 lyase inhibitor, particularly, a compound represented by the formula (I): wherein n is an integer of 1 to 3, and Ar is an aromatic ring optionally having substituent(s), or a salt thereof or a prodrug thereof.
    Type: Application
    Filed: February 5, 2014
    Publication date: September 11, 2014
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Masuo Yamaoka, Takahito Hara
  • Publication number: 20100261689
    Abstract: The present invention mainly aims to provide a drug for the prophylaxis or treatment of androgen-independent prostate cancer, which is highly useful as a pharmaceutical agent. The present invention provides a drug for the prophylaxis or treatment of androgen-independent prostate cancer, containing a steroid C17,20 lyase inhibitor, particularly, a compound represented by the formula (I): wherein n is an integer of 1 to 3, and Ar is an aromatic ring optionally having substituent(s), or a salt thereof or a prodrug thereof.
    Type: Application
    Filed: October 28, 2008
    Publication date: October 14, 2010
    Inventors: Masuo Yamaoka, Takahito Hara
  • Publication number: 20100119452
    Abstract: It is intended to provide a screening method of a compound having an effect of inhibiting the production of a prostatic specific antigen and/or an effect of suppressing the proliferation of androgen-independent prostatic cancer, comprising using an androgen-independent human prostatic cancer cell.
    Type: Application
    Filed: June 12, 2008
    Publication date: May 13, 2010
    Inventors: Takahito Hara, Masuo Yamaoka
  • Publication number: 20090169610
    Abstract: The present invention provides cancer treatment preparations of excellent targetability. The sugar chain-modified liposomes of the present invention, which contain an aromatase inhibitor, anti-androgenic agent, lyase inhibitor, GnRH agonist, GnRH antagonist, anti-angiogenic agent, tyrosine kinase inhibitor, serine-threonine kinase inhibitor, antibody having an anticancer activity, ansamitocin, capecitabine, celmoleukin, docetaxel hydrate, gemcitabine hydrochloride, oxaliplatin, prednisolone, tegafur-uracil mixtures, zinostatin stimalamer or arsenic trioxide may be used as cancer treatment preparations having an excellent targetability.
    Type: Application
    Filed: February 2, 2007
    Publication date: July 2, 2009
    Inventors: Noboru Yamazaki, Sei Yoshida, Masuo Yamaoka, Akira Hori, Shigeya Kakimoto, Shuichi Furuya
  • Publication number: 20090042857
    Abstract: A tissue-selective androgen receptor modulator containing a compound represented by the formula wherein Ring A represents an optionally substituted 5- to 8-membered ring, Ring B represents an optionally further substituted 4- to 10-membered ring, Ring C represents an optionally further substituted benzene ring, X1 represents an optionally substituted carbon atom, X2 represents an optionally substituted carbon atom, an oxygen atom and the like, W1 represents a nitrogen atom and the like, Y11 represents a group represented by the formula CR2R3? (wherein R2 represents a hydrogen atom, a cyano group, a nitro group and the like, and R3? represents a bond, a hydrogen atom, a cyano group, a nitro group and the like, respectively), Y21 represents a group represented by the formula CR4R5? (wherein R4 represents a hydrogen atom, a cyano group, a nitro group and the like, and R5? represents a bond, a hydrogen atom, a cyano group, a nitro group and the like, respectively) and the like, R1 represents an electron-withd
    Type: Application
    Filed: February 19, 2007
    Publication date: February 12, 2009
    Inventors: Masuo Yamaoka, Takahito Hara, Satoshi Yamamoto
  • Patent number: 7084149
    Abstract: A composition containing a compound of the formula: wherein A is a nitrogen-containing heterocyclic group which may be substituted, R1 is a hydrogen atom, hydrocarbon group which may be substituted, or monocyclic aromatic heterocyclic group which may be substituted, R2 is a hydrogen atom or a lower alkyl group which may be substituted, R3, R4, R5, R6, R7, R8 and R9 are independently a hydrogen atom, a hydrocarbon group which may be substituted, a hydroxy group which may be substituted, a thiol group which may be substituted, an amino group which may be substituted, an acyl group or a halogen atom, a salt thereof or a prodrug thereof has steroid C17,20-lyase inhibitory activity, and are useful for preventing and treating a mammal suffering from, for example, primary cancer of malignant tumor, its metastasis and recurrence thereof.
    Type: Grant
    Filed: May 22, 2003
    Date of Patent: August 1, 2006
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Akihiro Tasaka, Akio Ojida, Tomohiro Kaku, Masami Kusaka, Masuo Yamaoka
  • Patent number: 7067537
    Abstract: The present invention provides a pharmaceutical composition having a steroid C17,20-lyase inhibitory activity, which is useful as a prophylactic or therapeutic agent of prostatism, tumor such as breast cancer and the like, more particularly, a steroid C17,20-lyase inhibitor containing a compound represented by the formula: wherein A1 is an aromatic hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, one of A2 and A3 is a hydrogen atom, a halogen atom, a C1-4 aliphatic hydrocarbon group optionally having substituents or an optionally esterified carboxyl group, the other of A2 and A3 is an aromatic hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, and at least one of A1, A2 and A3 is a 3-pyridyl group optionally having substituents, or a salt thereof or a prodrug thereof.
    Type: Grant
    Filed: December 7, 2001
    Date of Patent: June 27, 2006
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Noritaka Kuroda, Yoshi Nara, Shohei Hashiguchi, Akihiro Tasaka, Masami Kusaka, Masuo Yamaoka, Tomohiro Kaku
  • Publication number: 20040072876
    Abstract: The present invention provides a pharmaceutical composition having a steroid C17,20-lyase inhibitory activity, which is useful as a prophylactic or therapeutic agent of prostatism, tumor such as breast cancer and the like, more particularly, a steroid C17,20-lyase inhibitor containing a compound represented by the formula: 1
    Type: Application
    Filed: June 4, 2003
    Publication date: April 15, 2004
    Inventors: Noritaka Kuroda, Yoshi Nara, Shohei Hashiguchi, Akihiro Tasaka, Masami Kusaka, Masuo Yamaoka, Tomohiro Kaku
  • Publication number: 20030236274
    Abstract: A composition containing a compound of the formula: 1
    Type: Application
    Filed: May 22, 2003
    Publication date: December 25, 2003
    Inventors: Akihiro Tasaka, Akio Ojida, Tomohiro Kaku, Masami Kusaka, Masuo Yamaoka
  • Patent number: 6649643
    Abstract: Imidazol-4-ylmethanols and their uses for preventing and treating primary tumors, metastasis and recurrence of tumors, various symptoms accompanying tumors, prostatic hypertrophy, virilism, hirsutism, male pattern alopecia, precocious puberty, endometriosis, uterine myoma, mastopathy and polycystic ovary syndrome are disclosed.
    Type: Grant
    Filed: April 12, 2002
    Date of Patent: November 18, 2003
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Akihiro Tasaka, Akio Ojida, Tomohiro Kaku, Masami Kusaka, Masuo Yamaoka
  • Patent number: 6573289
    Abstract: A composition containing a compound of the formula: wherein A is a nitrogen-containing heterocyclic group which may be substituted, R1 is a hydrogen atom, hydrocarbon group which may be substituted, or monocyclic aromatic heterocyclic group which may be substituted, R2 is a hydrogen atom or a lower alkyl group which may be substituted, R3, R4, R5, R6, R7, R8 and R9 are independently a hydrogen atom, a hydrocarbon group which may be substituted, a hydroxy group which may be substituted, a thiol group which may be substituted, an amino group which may be substituted, an acyl group or a halogen atom, a salt thereof or a prodrug thereof has steroid C17,20-lyase inhibitory activity, and is useful for preventing and treating for example, primary cancer of malignant tumor, its metastasis and recurrence thereof.
    Type: Grant
    Filed: October 18, 2000
    Date of Patent: June 3, 2003
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Akihiro Tasaka, Akio Ojida, Tomohiro Kaku, Masami Kusaka, Masuo Yamaoka
  • Patent number: 6420375
    Abstract: To provide a novel compound of the formula: [wherein A1 ix a 5 or 6-membered ring which may be substituted by a group not containing a cyclic group, A2 is an aromatic ring which may be substituted, X is a divalent group, Y is a nitrogen atom or a methine group, Z is an ethenylene which may be substituted or ethynylene, R is a heterocyclic group which may be substituted, provided that 3,4-dihydro-6-[3-(1H-imidazol-1-yl)-1-propenyl]-2(1H)-quinolone and 2-[3-[5-ethyl-6-methyl-2-(benzyloxy)-3-pyridyl]-1-propenyl]benzoxazole are excluded.], or a salt thereof which has steroid C17,20-lyase inhibitory activity, and is useful for preventing and treating mammals suffering from, for example, primary cancer of malignant tumor, its metastasis and recurrence thereof.
    Type: Grant
    Filed: August 18, 1999
    Date of Patent: July 16, 2002
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Tetsuya Aono, Fumio Itoh, Tomohiro Kaku, Masuo Yamaoka
  • Patent number: 5753664
    Abstract: A novel compound of the formula:A--Z--Ar.sup.1 1'CO--Ar.sup.2wherein A is a condensed pyrimidinone or condensed pyridazinone ring; Ar.sup.1 and Ar.sup.2 are independently a ring; Z is a divalent group, or a salt thereof which have an excellent antitumor activity.
    Type: Grant
    Filed: March 13, 1996
    Date of Patent: May 19, 1998
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Tetsuya Aono, Shogo Marui, Fumio Itoh, Masuo Yamaoka, Masafumi Nakao